Adamson, SJ, Sellman, JD, Foulds, JA, Frampton, CM, Deering, D, Dunn, A, Berks, J, Nixon, L and Cape, G (2015) A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression. Journal of Clinical Psychopharmacology 35, 143–149.
American Psychiatric Association (1980) Diagnostic and Statistical Manual of Mental Disorders-DSM III. Washington, DC.
American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders-DSM III-R. Washington, DC.
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders-DSM IV. Washington, DC.
Arroll, B, Elley, CR, Fishman, T, Goodyear-Smith, FA, Kenealy, T, Blashki, G, Kerse, N and MacGillivray, S (2009) Antidepressants versus placebo for depression in primary care. Cochrane Database of Systematic Reviews 2009, CD007954.
Bagul, NB and Kirkham, JJ (2012) The reporting of harms in randomized controlled trials of hypertension using the CONSORT criteria for harm reporting. Clinical and Experimental Hypertension 34, 548–554.
Ball, WA, Snavely, DB, Hargreaves, RJ, Szegedi, A, Lines, C and Reines, SA (2014) Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder. Human Psychopharmacology 29, 568–577.
Boesen, K, Paludan-Müller, AS and Munkholm, K (2018) Network meta-analysis of antidepressants. Lancet 392, 1011–1012.
Cipriani, A, Furukawa, TA, Salanti, G, Chaimani, A, Atkinson, LZ, Ogawa, Y, Leucht, S, Ruhe, HG, Turner, EH, Higgins, JP and Egger, M (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 391, 1357–1366.
Claghorn, JL, Earl, CQ, Walczak, DD, Stoner, KA, Wong, LF, Kanter, D and Houser, VP (1996) Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients. Journal of Clinical Psychopharmacology 16, 113–120.
Eyding, D, Lelgemann, M, Grouven, U, Härter, M, Kromp, M, Kaiser, T, Kerekes, MF, Gerken, M and Wieseler, B (2010) Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. British Medical Journal 341, c4737.
Feighner, JP and Overo, K (1999) Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. The Journal of Clinical Psychiatry 60, 824–830.
Feighner, JP, Robins, E, Guze, SB, Woodruff, RA, Winokur, G and Munoz, R (1972) Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry 26, 57–63.
Forest Laboratories Inc (2001) Study no. SCT-MD-01. Unpublished Data, Study Report from U.S. Food and Drug Administration.
Fournier, JC, Derubeis, RJ, Hollon, SD, Dimidjian, S, Amsterdam, JD, Shelton, RC and Fawcett, J (2010) Antidepressant drug effects and depression severity: a patient-level meta-analysis. Journal of the American Medical Association 303, 47–53.
Furukawa, TA, Salanti, G, Atkinson, LZ, Leucht, S, Ruhe, HG, Turner, EH, Chaimani, A, Ogawa, Y, Takeshima, N, Hayasaka, Y and Imai, H (2016) Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis. British Medical Journal 6, e010919.
Gastpar, M, Singer, A and Zeller, K (2006) Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a doubleblind, randomised, multicentre, placebo-controlled study. Pharmacopsychiatry 39, 66–75.
Gibbons, RD, Hur, K, Brown, CH, Davis, JM and Mann, JJ (2012) Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Archives of General Psychiatry 69, 572–579.
Goldstein, DJ, Lu, Y, Detke, MJ, Wiltse, C, Mallinckrodt, C and Demitrack, MA (2004) Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. Journal of Clinical Psychopharmacology 24, 389–399.
Goldstein, DJ, Mallinckrodt, C, Lu, Y and Demitrack, MA (2002) Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. Journal of Clinical Psychopharmacology 63, 225–231.
Gøtzsche, PC (2017) Antidepressants increase the risk of suicide, violence and homicide at all ages. British Medical Journal 358, j3697.
Haidich, A-B, Birtsou, C, Dardavessis, T, Tirodimos, I and Arvanitidou, M (2011) The quality of safety reporting in trials is still suboptimal: survey of major general medical journals. Journal of Clinical Epidemiology 64, 124–135.
Hieronymus, F, Emilsson, JF, Nilsson, S and Eriksson, E (2016) Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. Molecular Psychiatry 21, 523–530.
Hieronymus, F, Lisinski, A, Näslund, J and Eriksson, E (2018a) Katakam and co-workers have not shown SSRIs to be harmful and ineffective and should stop claiming that they have. Acta Neuropsychiatrica 2018, 1–9.
Hieronymus, F, Lisinski, A, Näslund, J and Eriksson, E (2018b) Multiple possible inaccuracies cast doubt on a recent report suggesting selective serotonin reuptake inhibitors to be toxic and ineffective. Acta Neuropsychiatrica 30, 244–250.
Higgins, JP and Green, S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration. Available at http://www.cochrane-handbook.org (accessed 09 September 2018).
Hodkinson, A, Kirkham, JJ, Tudur-Smith, C and Gamble, C (2013) Reporting of harms data in RCTs: a systematic review of empirical assessments against the CONSORT harms extension. BMJ Open 3, e003436.
Hróbjartsson, A, Emanuelsson, F, Skou Thomsen, AS, Hilden, J and Brorson, S (2014) Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies. International Journal of Epidemiology 43, 1272–1283.
Hróbjartsson, A, Thomsen, AS, Emanuelsson, F, Tendal, B, Hilden, J, Boutron, I, Ravaud, P and Brorson, S (2012) Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. British Medical Journal 344, e1119.
Hróbjartsson, A, Thomsen, AS, Emanuelsson, F, Tendal, B, Hilden, J, Boutron, I, Ravaud, P and Brorson, S (2013) Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. Canadian Medical Association Journal 185, E201–E211.
Hughes, S, Cohen, D and Jaggi, R (2014) Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study. BMJ Open 4, e005535.
Ioannidis, JP (2008) Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials? Philosophy, Ethics, and Humanities in Medicine 3, 14.
Ioannidis, JP (2009) Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Archives of Internal Medicine 169, 1737–1739.
Jakobsen, JC, Katakam, KK, Schou, A, Hellmuth, SG, Stallknecht, SE, Leth-Møller, K, Iversen, M, Banke, MB, Petersen, IJ, Klingenberg, SL and Krogh, J (2017a) Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. BMC Psychiatry 17, 58.
Jakobsen, JC, Lindschou, J, Hellmuth, S, Schou, A, Krogh, J and Gluud, C (2013a) The effects of selective serotonin reuptake inhibitors versus no intervention, placebo, or ‘active’ placebo in patients with major depressive disorder. A systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. PROSPERO, CRD42013004420. Available at http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42013004420
Jakobsen, JC, Simonsen, E, Rasmussen, KB and Gluud, C (2013b) Is the total score of the Hamilton Depression Rating Scale associated with suicide attempts or suicides? British Journal of Medical Research 3, 140–152.
Jindal, RD, Friedman, ES, Berman, SR, Fasiczka, AL, Howland, RH and Thase, ME (2003) Effects of sertraline on sleep architecture in patients with depression. Journal of Clinical Psychopharmacology 23(6), 540–548.
Katakam, KK, Sethi, NJ, Jakobsen, JC and Gluud, C (2018) Great boast, small roast on effects of selective serotonin reuptake inhibitors: response to a critique of our systematic review. Acta Neuropsychiatrica 30(5), 251–265.
Keller, M, Montgomery, S, Ball, W, Morrison, M, Snavely, D, Liu, G, Hargreaves, R, Hietala, J, Lines, C, Beebe, K and Reines, S (2006) Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biological Psychiatry 59, 216–223.
Khan, A, Leventhal, RM, Khan, SR and Brown, WA (2002) Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. Journal of Clinical Psychopharmacology 22, 40–45.
Kirsch, I, Deacon, BJ, Huedo-Medina, TB, Scoboria, A, Moore, TJ and Johnson, BT (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine 5(2), e45.
Leucht, S, Fennema, H, Engel, R, Kaspers-Janssen, M, Lepping, P and Szegedi, A (2013) What does the HAMD mean? Journal of Affective Disorders 148, 243–248.
Lewer, D, O’reilly, C, Mojtabai, R and Evans-Lacko, S (2015) Antidepressant use in 27 European countries: associations with sociodemographic, cultural and economic factors. The British Journal of Psychiatry 207, 221–226.
Liu, KS, Snavely, DB, Ball, WA, Lines, CR, Reines, SA and Potter, WZ (2008) Is bigger better for depression trials? Journal of Psychiatric Research 42, 622–630.
Lundh, A, Lexchin, J, Mintzes, B, Schroll, JB and Bero, L (2017) Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2, MR000033.
Mancino, MJ, Mcgaugh, J, Chopra, MP, Guise, JB, Cargile, C, Williams, DK, Thostenson, J, Kosten, TR, Sanders, N and Oliveto, A (2014) Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms. Journal of Clinical Psychopharmacology 34, 234–239.
Massana, J (1998) Reboxetine versus fluoxetine: an overview of efficacy and tolerability. The Journal of Clinical Psychiatry 59, 8–10.
Mathews, M, Gommoll, C, Chen, D, Nunez, R and Khan, A (2015) Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial. International Clinical Psychopharmacology 30, 67.
Moncrieff, J and Kirsch, I (2015) Empirically derived criteria cast doubt on the clinical significance of antidepressant-placebo differences. Contemporary Clinical Trials 43, 60–62.
Olfson, M, Marcus, SC and Shaffer, D (2006) Antidepressant drug therapy and suicide in severely depressed children and adults: A case-control study. Archives of General Psychiatry 63(8), 865–872.
Péron, J, Maillet, D, Gan, HK, Chen, EX and You, B (2013) Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review. Journal of Clinical Oncology 31, 3957–3963.
Pettinati, HM, Oslin, DW, Kampman, KM, Dundon, WD, Xie, H, Gallis, TL, Dackis, CA and O'Brien, CP (2010) A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. The American Journal of Psychiatry 167, 668–675.
Pharmacia & Upjohn (2001a) Reboxetine (PNU-155950E) Versus Placebo and Fluoxetine in a Controlled, Randomized, Double-Blind, Multicenter Study of Treatment in Major Depressive Disorders: Final Report of the Study Protocol 97-CRBX-050. Available at http://www.iqwig.de/download/Studie_050.pdf (accessed 09 September 2018). Pharmacia & Upjohn (2001b) Reboxetine, Placebo, and Paroxetine Comparison in Patients with Major Depressive Disorder: A Phase III, Randomized, Double-Blind, Placebo- and Active Treatment-Controlled, Parallel-Group, 8-Week Study of Reboxetine, Given Orally Twice Daily to Adult Patients with Major Depressive Disorder; Final Report of The Study Protocol M/2020/0046. Available at http://www.iqwig.de/download/Studie_046.pdf (accessed 09 September 2018). Pharmacia & Upjohn (2001c) Reboxetine, Placebo, and Paroxetine Comparison in Patients with Major Depressive Disorder: A Phase III, Randomized, Double-Blind, Placebo- and Active treatment-Controlled, Parallel-Group, 8-Week Study of Reboxetine, Given Orally Twice Daily To Adult Patients with Major Depressive Disorder: Final Report of The Study Protocol M/2020/0047. Available at http://www.iqwig.de/download/Studie_047.pdf (accessed 09 September 2018).
Ravindran, AV, Teehan, MD, Bakish, D, Yatham, L, O’reilly, R, Fernando, ML, Manchanda, R, Charbonneau, Y and Buttars, J (1995) The impact of sertraline, desipramine, and placebo on psychomotor functioning in depression. Human Psychopharmacology 10, 273–281.
Savović, J, Jones, HE, Altman, DG, Harris, RJ, Jüni, P, Pildal, J, Als-Nielsen, B, Balk, EM, Gluud, C, Gluud, LL and Ioannidis, JP (2012) Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 157, 429–438.
Sharma, T, Guski, LS, Freund, N and Gøtzsche, PC (2016) Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. British Medical Journal 352, i65.
Shukralla, AA, Tudur-Smith, C, Powell, GA, Williamson, PR and Marson, AG (2011) Reporting of adverse events in randomised controlled trials of antiepileptic drugs using the CONSORT criteria for reporting harms. Epilepsy Research 97, 20–29.
Smith, SM, Chang, RD, Pereira, A, Shah, N, Gilron, I and Katz, NP (2012) Adherence to CONSORT harms-reporting recommendations in publications of recent analgesic clinical trials: an ACTTION systematic review. PAIN 153, 2415–2421.
Sutton, AJ, Duval, S, Tweedie, R, Abrams, KR and Jones, DR (2000) Empirical assessment of effect of publication bias on meta-analyses. British Medical Journal 320, 1574–1577.
Sweeting, MJ, Sutton, AJ and Lambert, PC (2004) What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Statistics in Medicine 23, 1351–1375.
Timimi, S, Moncrieff, J, Gøtzche, P, Davies, J, Kinderman, P, Byng, R, Montagu, L and Read, J (2018) Network meta-analysis of antidepressants. Lancet 392, 1011–1012.
Turner, EH, Matthews, AM, Linardatos, E, Tell, RA and Rosenthal, R (2008) Selective publication of antidepressant trials and its influence on apparent efficacy. The New England Journal of Medicine 358, 252–260.
Undurraga, J and Baldessarini, RJ (2012) Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology 37, 851.
Warren, J (2018) Network meta-analysis of antidepressants. Lancet 392, 1010–1011.
Wernicke, JF, Dunlop, SR, Dornseif, BE, Bosomworth, JC and Humbert, M (1988) Low-dose fluoxetine therapy for depression. Psychopharmacology Bulletin 24, 183–188.
World Health Organization (1993) The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Geneva, Switzerland: WHO.